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A B S T R A C T
The discovery of rare familial monogenic forms of early-onset Parkinson’s disease has led to the identiﬁcation of
a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes
encoding PINK1 or Parkin result in insuﬃcient removal of dysfunctional mitochondria through autophagy, a
process termed mitophagy. Understanding the mechanism of this process and the function of its two key players,
PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mito-
phagy, either activating PINK1 or Parkin directly or inhibiting Parkin’s counterplayer, the ubiquitin-speciﬁc
protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy
enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after
the discovery of mitophagy deﬁcits in Parkinson’s disease, research of the underlying mechanisms, drug dis-
covery of modulators for this mechanism and identiﬁcation of biomarkers provide new avenues towards the
development of disease-modifying therapies.
1. Introduction
Parkinson's disease (PD) is the second most common neurodegen-
erative disorder and is characterized clinically by tremor, rigidity,
bradykinesia and postural instability. Pathologically, the disease is as-
sociated with loss of dopaminergic neurons in the substantia nigra,
decreased dopamine neurotransmission and the presence of neuronal
intracellular Lewy body inclusions [64]. Current treatments for PD al-
leviate the symptoms of parkinsonism in the ﬁrst years after diagnosis,
but become less eﬀective as the neurodegeneration advances and there
are no therapies currently available that prevent the onset or progres-
sion of the disease. Therefore, it is of great importance to understand
the molecular basis of PD so that therapeutic breakthroughs can be
made in the near future. Several lines of evidence suggest that mi-
tochondrial dysfunction is central to the disease [39] including the
observations that mitochondrial toxins cause parkinsonism in humans
and animal models, that PD patients have systemic mitochondrial
complex I deﬁcits, and that dopaminergic neurons in elderly individuals
accumulate high levels of mitochondrial DNA (mtDNA) mutations re-
lative to other neuronal subtypes [5,18,22,56,98]. Discovery of rare
familial monogenic forms of PD has provided insights into the patho-
genic mechanisms of mitochondrial dysfunction in PD and provided
new targets to pursue for drug development [103]: Early-onset
autosomal recessive Parkinson’s disease can be caused by mutations in
the ubiquitin ligase Parkin and protein kinase, PTEN-induced kinase 1
(PINK1) [50,111], both of which maintain a healthy mitochondrial
network by stimulating removal of dysfunctional parts through selec-
tive autophagy, a process termed mitophagy [76]. The current model is
that in functional mitochondria, i.e. those with an intact membrane
potential, PINK1 is imported into mitochondria and subsequently
cleaved by the protease, presenilins-associated rhomboid-like protein
(PARL) [47], leading to its degradation via the N-end rule pathway
[38]. However, in response to mitochondrial membrane depolarisation,
PINK1 [111] is not cleaved and accumulates on the outer membrane of
mitochondria where it phosphorylates ubiquitin on outer mitochondrial
membrane (OMM) proteins at Serine 65 (Ser65) [48,49,55]. Phos-
phorylated ubiquitin at Ser65 (pS65-Ub) triggers the recruitment of
Parkin to the OMM [47], whereupon it is phosphorylated by PINK1 at
an equivalent Ser65 residue within its N-terminal ubiquitin-like domain
[54]. This stimulates the ubiquitin-ligase activity of Parkin resulting in
ubiquitination of multiple OMM proteins, such as the voltage-depen-
dent anion channel 1 and mitofusin 2 [81,95]. This creates a feed-for-
ward mechanism where newly assembled ubiquitin is phosphorylated
by PINK1, which in turn promotes further Parkin recruitment [82]. The
accumulation of pS65-Ub chains on the OMM is reported to stimulate
the recruitment of ubiquitin adaptor proteins including optineurin and
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nuclear dot protein 52 kDa (NDP52), and TAXBP1 which promote en-
gulfment of the depolarized mitochondria by autophagosomes
[40,62,118]. However, recent studies have suggested that pS65-Ub
chains inhibit adaptor protein recruitment [80]. Furthermore, con-
ﬂicting ﬁndings have been reported for p62/sequestosome 1 (SQSTM1)
as the adaptor for ubiquitinated mitochondria [26,62,75,78,118].
2. Evidence for mitophagy in vivo
Most of the current understanding of PINK1 and Parkin mediated
mitophagy stems from studies in cell lines overexpressing Parkin that
are treated with high concentrations of mitochondrial uncouplers such
as carbonyl cyanide m-chlorophenyl hydrazine (CCCP) or depolarizing
agents such as antimycin alone or in combination with oligomycin.
Evidence that the PINK1/Parkin pathway is active in vivo was ﬁrst
provided by studies in Drosophila showing that deﬁciency of PINK1 or
Parkin triggers the accumulation of enlarged, dysfunctional mitochon-
dria in sperm, ﬂight muscle and dopaminergic neurons [10,35,85,120].
Moreover, a proteomics approach revealed that the half-life of several
mitochondrial proteins was increased in Parkin mutant ﬂies in a pattern
similar to that of autophagy-defective Atg7 mutants, thus supporting a
role for Parkin in mitophagy [113]. Diﬀerent reporters have been used
to image mitophagy directly in ﬂies, but yielded discrepant results [12].
In one study, ﬂies expressing the mitochondrial reporter mtKeima
whose ﬂuorescence changes when mitochondria are degraded in the
lysosome, indicated a potential role for PINK1 and Parkin in age-de-
pendent mitophagy [12]. In contrast, in another study, ﬂies expressing
mtKeima or the alternate mitoQC reporter, a mCherry-GFP tandem
construct fused to the mitochondrial ﬁssion protein (Fis), in which GFP
is quenched in the lysosome, did not demonstrate PINK1-dependent
mitophagy [63]. Studies in rodents have also produced equivocal re-
sults. While mice expressing the mitoQC reporter show robust levels of
basal mitophagy in dopaminergic neurons in the midbrain, crossing
these mice with PINK1 knockout (KO) or ParkinS65A/S65A mutant mice
did not signiﬁcantly alter basal mitophagy levels [70,71]. However, KO
mice lacking PINK1 or Parkin genes show subtle behavioral and neu-
rochemical abnormalities and no overt dopaminergic neuron degen-
eration [2,31,34,51,86] and therefore have been unable to address the
contribution of PINK1 and Parkin to stress-evoked mitophagy in vivo.
PINK1, but not Parkin KO rats showed progressive nigral neurodegen-
eration with about 50% dopaminergic cell loss observed at 8 months of
age [15] and the reasons for this diﬀerence are not known. Crossing
mouse models of mitochondrial dysfunction with Parkin KO mice has
also produced mixed results: Mice with KO of the mitochondrial bio-
genesis transcription factor A (TFAM) in dopaminergic neurons did not
show Parkin-dependent dopaminergic cell loss [106]. However, en-
hanced parkinsonian-like neurodegeneration has been observed by
crossing Parkin KO mice with mouse models of mitochondrial DNA
(mtDNA) mutations, including mutator mice that lack the mitochon-
drial DNA polymerase gamma subunit (POLG) and accumulate mtDNA
mutations [87], Twinkle (an essential mitochondrial helicase) trans-
genic mice in which mtDNA deletions are increased speciﬁcally in
substantia nigra [105] and PD-mito-PstI mice, where mtDNA undergoes
double-strand breaks only in dopaminergic neurons [88]. Mt-Keima
mice have not yet been employed to assess whether mitophagy is ele-
vated in these mice lines [57]. However, recently it was observed that
exhaustive exercise led to an elevation of mitophagy in heart muscle
using the mt-Keima reporter line and critically, this was prevented in
mice lacking PINK1 [104]. This represents the strongest evidence to
date in mammalian models for an essential role of PINK1 in stress-
evoked mitophagy in vivo [104]. Relatively modest morphological or
functional changes in mitochondria have been observed in iPSC-derived
neurons with PINK1 [72,93,99] or Parkin mutations [9,43,46,100] and
analysis of mitophagy in these neuronal systems using either mt-Keima
or mitoQC reporter assays is awaited.
Finally, accumulation of pS65-Ub was demonstrated in postmortem
brains from elderly human subjects [23] and in subjects with Lewy
body disease [24], supporting the notion that the PINK1/Parkin
pathway is active in human brain during aging and disease states.
3. Role of PINK1/ Parkin mediated mitophagy in inﬂammation
How can we reconcile the modest phenotypes caused by loss of
PINK1 or Parkin in rodent models or human iPSC-derived dopaminergic
neurons with the development of early onset Parkinson’s disease in
humans? A recent study suggests that a more systemic view beyond
dopaminergic neurodegeneration may be required to fully understand
the consequences of dysfunctional mitophagy [104]: Using an ex-
haustive exercise experimental paradigm the authors show that PINK1/
Parkin mediated mitophagy restrains innate immunity in vivo and that
dysfunction in mitophagy leads to upregulation of the stimulator of
interferon genes (STING) pathway causing an inﬂammatory phenotype
that ultimately may contribute to the loss of dopaminergic neurons
[104]. Importantly, components of innate immunity activation are also
found in patients with Parkin mutations [104]. Supporting a role for
PINK1 and Parkin in immune responses, PINK1 and Parkin were shown
to mediate mitochondrial antigen presentation and trigger adaptive
immune responses in a mouse macrophage cell line through mi-
tochondrial-derived vesicles [69]. PINK1 KO mice show changes in
innate immunity and inﬂammation early during the progression of
pathology [107]. Parkin KO increases vulnerability to inﬂammation-
related nigral degeneration by lipopolysaccharide injections [25]. A
vicious cycle has been proposed whereby inﬂammation leads to more
mitochondrial damage and that promotes further inﬂammatory pro-
cesses [112]. It may therefore be that synergy between mitochondrial
dysfunction and immune responses is required for Parkinson’s disease
to develop and that many rodent models only reproduce part of the
systemic dysfunction.
4. Therapeutic approaches to enhance PINK1/Parkin mediated
mitophagy
To ameliorate the consequences of mitochondrial dysfunction
leading PD pathology, several therapeutic approaches are being ex-
plored (Fig. 1).
4.1. PINK1 activators
PINK1 is highly conserved across species and this had led to iden-
tiﬁcation of insect PINK1 homologues including Pediculus humanus
corporis PhPINK1 [33] and Tribolium castaneum TcPINK1 [58,79,119],
that can be expressed in suﬃcient quantities in E.coli to study the
structure and substrate recognition mechanisms of PINK1 and under-
stand the impact of the autosomal recessive mutations in PD. PINK1 is
distinct from other protein kinases due to the presence of three unique
insertions within the kinase domain and a C-terminal region of un-
known function with no homology to any known protein [66]. Almost
30 missense and nonsense human PINK1 (hPINK1) mutations have been
reported in patients [17] that are located predominantly within the
kinase domain or predicted to truncate the C-terminal region
[33,58,79]. PINK1 rapidly accumulates on the OMM when mitochon-
dria become depolarized and forms a large 700 kDa multimeric com-
plex with the translocase of the outermembrane (TOM) complex [4,61],
which in turn triggers autophosphorylation and activation of PINK1
[77,80]. Three autophosphorylation sites have been conﬁrmed for
hPINK1, Thr257 [54], Ser228 and Ser402, of which the latter two in-
ﬂuence Parkin and subsequent ubiquitin phosphorylation [1]. Ser402 is
located in the conserved activation loop of hPINK1, which is predicted
to maximize kinase activity upon autophosphorylation through inter-
action with residues in the catalytic motif and stabilization of the active
conformation [102]. Ser402 autophosphorylation and activation of
hPINK1 increases Parkin recruitment and conversely, lack of
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autophosphorylation attenuates Parkin recruitment [102]. Ser228 au-
tophosphorylation increases substrate phosphorylation in vitro, but it is
dispensable for Parkin recruitment and the initiation of mitophagy
[1,80]. Instead, structural data of insect PINK1 suggest that phosphor-
ylation in the N-lobe, in particular of Ser202 (phPINK) or Ser205
(TcPINK1), respectively (corresponding to human Ser228), is crucial for
kinase integrity and activity, as well as for ubiquitin binding to the N-
lobe [33,58,79]. Small-molecule activation of PINK1 could be accom-
plished by increasing dimerization or enhancing autophosphorylation
through binding to allosteric regulatory sites. Alternatively, ubiquitin
conformational modulators are proposed to increase ubiquitin phos-
phorylation levels [28]. A third approach to increase in PINK1 activity
in vitro is achieved using a neo-substrate, i.e. the ATP analogue kinetin
triphosphate [41,84], WO-2015/123365. No eﬀects of kinetin were
detectable in PINK1 KO rats after oral dosing for up to 6 months, but
also no dopaminergic neurodegeneration was observed in this study
leaving the question open whether kinetin could mitigate pathology
induced by PINK1 KO [83]. Future studies will show whether any of
these approaches can yield eﬃcacious small molecules for translation in
animal models and ultimately, in humans.
4.2. Parkin Activators
Parkin belongs to the RBR [RING– in-between-RING (IBR)–RING]
family of E3 ligases, which contain a RING1 domain for E2 recruitment,
a catalytic domain (RING2) through which transfer of ubiquitin is
mediated, and a linking IBR domain [116]. Parkin comprises ﬁve do-
mains: ubiquitin-like domain (Ubl), RING0, RING1, IBR, and RING2.
The Ubl and RING0 domains are unique to Parkin, but the RBR module
is common to all RBR ligases. In Parkin-associated PD more than hun-
dred diﬀerent mutations have been identiﬁed that result in deletions,
truncations and exon duplications, all of which lead to a loss of function
of Parkin [13,54]. PD associated Parkin mutations are distributed
across all ﬁve domains and are also found within interfaces between
domains and in linker regions suggesting that the structural integrity of
all domains is important in PD pathogenesis [115]. Structures of Parkin
show that under basal conditions it adopts an autoinhibited con-
formation mediated by its N-terminal Ubl domain through three me-
chanisms [8,57,109]: First, the RING0 domain partially occludes the
catalytic cysteine (Cys431). Second, a small helical repressor element of
Parkin (REP) together with the Ubl domain blocks the predicted E2
binding site on RING1. Third, the distance between the RING2 catalytic
cysteine and predicted E2 catalytic cysteine is over 30 Å, which is too
far to allow transfer of ubiquitin in the autoinhibited conformation of
Parkin [8,57,109]. Recent structural studies have revealed the me-
chanisms of Parkin activation and shown that the phosphorylated Ubl
binds to a site on the RING0 domain [32,97]. Furthermore, a conserved
linker region between the Ubl and RING0 domains functions as an ac-
tivating element to facilitate the release of the RING2 domain [32,97].
These new structures provide atomic insights into how to design Parkin
activators to disrupt the autoinhibitory mechanisms and stimulate
catalytic activity. It is currently not known whether ubiquitin transfer
occurs through conformational change or through cooperative binding
of multiple Parkin molecules [3]. Towards the development of small
molecule activators, an UbFluor probe has been described to precisely
quantitate changes in the activity of Parkin in response to phosphor-
ylation, allosteric activation by pUb, protein substrates, and activating
structural mutations [24]. Small molecule Parkin activators active in in
vitro assays have been described in WO-2018/023029 in addition to
assays to identify such molecules in WO-2010/011839, but no cellular
or in vivo data with Parkin activators are available to date.
4.3. Ubiquitin-speciﬁc protease (USP) 30 inhibitors
The actions of E3 ubiquitin ligases such as Parkin are regulated by
deubiquitinating enzymes (DUBs), which catalyze the removal of ubi-
quitin from substrates [53]. Due to the challenges with increasing
PINK1 or Parkin activity as outlined above, modulating DUBs involved
in mitophagy is an appealing approach for developing small molecule
activators of mitophagy. Two DUBs, USP15 and USP30 were shown to
oppose Parkin-mediated mitochondrial ubiquitination and mitophagy
in human cells in vitro and in Drosophila [6,11,12]. Another DUB,
USP8, was shown to activate mitophagy by removing ubiquitin residues
from Parkin and preventing its auto-inhibition [21]. USP30 is a parti-
cularly attractive drug target to selectively increase mitochondrial
ubiquitination, since it is localized at the OMM [74], where it pre-
ferentially hydrolyses Lys6 and Lys11-linked ubiquitin chains [14].
Original work by Bingol et al. showed that USP30 KO increases mito-
phagy in human cell lines overexpressing Parkin and rescues parkin-
sonian phenotypes in Drosophila expressing PINK1 or Parkin mutations
[6]. Several structures of USP30 have been solved and provide further
insights in its function [28,96]. USP30 is thought to fulﬁll a homeostatic
role by removing and recycling ubiquitin residues at the OMM [14].
When mitochondrial damage occurs, USP30 may help to limit Parkin
action and mitophagy to the site of damage [28]. Whether USP30 acts
Fig. 1. Therapeutic Strategies to Enhance
Mitophagy.
In healthy mitochondria PINK1 is imported
and cleaved by the protease PARL. Ubiquitin
residues are removed from OMM proteins by
USP30. Mitochondrial damage can occur
through natural processes and experimental
conditions, including mitochondrial complex I
(MC1) inhibition with MPP+ (the active me-
tabolite of MPTP) and rotenone. Upon mi-
tochondrial damage PINK1 locates to the
OMM, is activated by autophosphorylation and
recruits Parkin by phosphorylation on Ser65.
Phosphorylated Parkin ubiquitinates several
OMM proteins and the ubiquitin residues in
turn are phosphorylated on Ser65 by PINK1
creating a positive feed forward loop. The long
phosphorylated ubiquitin chains on OMM
proteins cannot be removed by USP30 culmi-
nating in engulfment of the mitochondrion by
autophagosomal membranes and recycling in
lysosomes. Mitophagy enhancing therapies are
aimed at increasing PINK1 and Parkin activity
and/or inhibiting USP30.
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upstream or downstream of PINK1 activation is not fully resolved.
Using both, mtKeima and mitoQC reporter systems it was shown in cells
in vitro that depletion of USP30 increases mitophagy, but not in the
absence of PINK1 [67]. These ﬁndings suggest that USP30 may act
upstream of PINK1 and prevent tonically active mitophagy [67]. The
same authors showed that USP30 depletion also increases the removal
of peroxisomes from cells, a process termed pexophagy, pointing to a
previously unknown regulatory role of USP30 in pexophagy [67]. Ef-
fects of USP30 KO in mice have not yet been published. To further
understand the therapeutic potential of USP30 inhibition for amelior-
ating mitophagy deﬁcits in Parkinson’s disease, several USP30 small
molecule inhibitors are under development by Mission Therapeutics
(11 patents describing selective small molecule inhibitors of USP30)
and Mitobridge LLC [52]. A natural molecule inhibiting USP30 has also
been described [36].
4.4. Novel targets
How can we ﬁnd novel targets in the PINK1/ Parkin pathway for
future drug development? Several high-content imaging based pheno-
typic screens have been published. Genome-wide siRNA screens for
modulators of CCCP-induced mitophagy in HeLa cells overexpressing
Parkin identiﬁed upstream regulators of Parkin [38] and ATPase in-
hibitory factor 1 as key players in this pathway [65]. A similar siRNA
screening paradigm in Drosophila cells discovered several targets in the
sterol regulatory element binding transcription factor (SREBF) lipo-
genesis pathway and showed that exogenous lipids can promote mito-
phagy [44]. A sophisticated chemogenomic approach able to detect
subtle increases in Parkin expression discovered epigenetic agents,
drugs controlling cholesterol biosynthesis and c-Jun N-terminal kinase
inhibitors that can enhance Parkin expression [37]. Finally, a genome-
wide CRISPR screen in SH-SY5Y neuroblastoma cells revealed a role for
the transcriptional repressor THAP domain-containing protein 11 in
regulating cellular Parkin and pUb levels [91]. Future research is ne-
cessary to validate these novel targets in neuronal cells in vitro and in
vivo.
5. Eﬃcacy and safety considerations for mitophagy enhancers
Activators of mitophagy may have a therapeutic beneﬁt for PD
patients beyond those with genetic mutations in the PINK1/ Parkin
pathway. Inactivation of Parkin due to post-translational modiﬁcations
has been reported in sporadic, late-onset PD [16,59,60,117]. In addi-
tion, mitochondrial dysfunction and mitochondrial complex I deﬁ-
ciency has been widely observed in PD [98,108]. And even if the mi-
tophagy pathway is not impaired in these patients, further boosting its
function may be beneﬁcial to clear dysfunctional mitochondria and
ameliorate pathology. However, removal of too many mitochondria
may aggravate pathology rather than mitigating it. Since mitophagy is a
complex pathway that is intricately regulated by other pathways, such
as lysosomal function and inﬂammation [89,112], unwanted side-ef-
fects, such as overwhelming the lysosomal system could also be an-
ticipated. PINK1, Parkin and USP30 serve cellular functions beyond
mitophagy and enhancing their function could cause dysregulation of
other cellular pathways (for recent reviews, see [67,94,101,114]). Due
to these potential safety concerns it is necessary to identify and stratify
Parkinson’s disease patients with mitochondrial dysfunction that may
most beneﬁt from mitophagy enhancing treatments and to carefully
monitor responses to therapeutic agents using biomarkers.
6. Biomarkers for mitochondrial dysfunction and mitophagy
As a direct measure of PINK1 and Parkin activity, pS65-Ub is a
promising biomarker [23,27]. A speciﬁc pS65-Ub antibody shows ac-
cumulation of pS65-Ub on mitochondria in brains from elderly human
subjects [23] and in patients with Lewy body disease [24] and could
potentially be used for enzyme-linked immunosorbent assay in human
bioﬂuids including cerebrospinal ﬂuid [23]. Alternatively, pS65-Ub can
be detected by mass spectrometry [104] and phosphoproteomics ap-
proaches may prove successful for detecting pS65-Ub in human bio-
ﬂuids [30,81]. A low abundance of pS65-Ub in cerebrospinal ﬂuid or
blood could be used to identify patients with defective mitophagy and
an increase in pS65-Ub in response to treatment with a mitophagy
enhancer could provide a pharmacodynamic read-out. Furthermore,
several biomarkers are being developed to monitor mitochondrial
health: A novel positron emission tomography (PET) tracer binds se-
lectively to mitochondrial complex one in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated monkeys [110] and is currently in
explorative clinical research by a pre-competitive consortium called
MIND-MAPS (https://goo.gl/Pl7H7C). If successful, this PET tracer may
help stratify PD patients with mitochondrial complex I deﬁciency and
indirectly monitor treatment response to mitophagy enhancing small
molecules by measuring the desired outcome of these therapies, i.e.
healthy mitochondria with normal mitochondrial complex I levels.
Multiple ﬂuid biomarkers of mitochondrial DNA integrity are also in
discovery, such as mtDNA copy number, methylation, deletions and
point mutations, and damage (for review, see [29,73]). A signiﬁcant
decrease in mtDNA copy number is observed in PD patient blood cells
independent of age and gender [36,92] correlating with changes ob-
served in postmortem brain [36,92], but see [20]. Reduced cell-free
circulating mtDNA levels in the cerebrospinal ﬂuid are detected in
early-stage Parkinson’s disease [92]. However, elevated levels of cell-
free circulating mtDNA levels were found in symptomatic PD patients
carrying LRRK2 mutations compared to asymptomatic LRRK2 mutation
carriers, idiopathic PD patients and controls [90] suggesting that more
studies are necessary to fully understand the time course of changes in
cell-free circulating mtDNA levels for biomarker purposes. Methylated
mitochondrial DNA (mtDNA) was reported to be reduced in the cere-
brospinal ﬂuid of PD patients, but with no association between age,
gender or clinical presentation and severity [42]. In postmortem PD
brains, the D-loop region of mtDNA, which is important for mi-
tochondrial transcription and replication, showed a loss of methylation
in nearly all CpG and non-CpG sites relative to control samples [7], but
further research is necessary to conﬁrm concordance between blood
and brain [45]. MtDNA sequence analysis has revealed an increasing
number of mutations associated with diverse clinical phenotypes,
however, speciﬁc PD-linked mutations have not been found [19]. Other
potential biomarkers of mitochondrial integrity are being researched in
animal models of PD, but will require further and independent vali-
dation in human postmortem brain tissue and bioﬂuids: Accumulation
of mono-oxygenated, mitochondria-speciﬁc cardiolipins is observed in
the substantia nigra and elevated levels of polyunsaturated cardiolipins
are detected in plasma of rats exposed to rotenone, a toxin-based animal
model of PD [68]. Taken together, on-target PINK1/Parkin activity
markers, such as pS65-Ub in combination with PET imaging and/or
bioﬂuid measures of mitochondrial integrity may enable clinical as-
sessment of small molecule mitophagy enhancers.
7. Conclusions
Targeting PINK1/Parkin mediated mitophagy is an emerging ther-
apeutic approach for the treatment of PD. Signiﬁcant progress has been
made since the discovery of the PINK1/Parkin pathway less than a
decade ago: Several small molecule drugs to enhance mitophagy are in
preclinical development as are exploratory biomarkers for mitochon-
drial dysfunction and mitophagy activation. Many questions remain
open with regards to selecting the most eﬀective and feasible targets in
the mitophagy pathway, possible side eﬀects of mitophagy enhance-
ment and the PD patient population that will most likely beneﬁt from
such treatments. Until these questions can be answered, mitophagy
research remains a promising new avenue for drug and biomarker de-
velopment.
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